Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Establishment and validation of the deep learning model of Cetuximab efficacy in simultaneous RAS wild unresectable CRLM patients

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Cetuximab

Criteria

Inclusion Criteria:

1. Age 18-75 years;

2. Histologically proven colorectal adenocarcinoma;

3. Simultaneous liver-limited metastases;

4. Initially unresectable liver metastases determined by a local MDT;

5. Life expectancy of > 6 months;

6. RAS and BRAF V600E wild-type;

7. ECOG 0-1;

8. Available CT imaging before treatment.

Exclusion Criteria:

1. Previous systemic treatment for metastatic disease;

2. Previous surgery for metastatic disease;

3. Extrahepatic metastases;

4. Unresectable primary tumor;

5. Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months before randomisation;

6. Acute or subacute intestinal obstruction;

7. Second primary malignancy within the past 5 years;

8. Drug or alcohol abuse;

9. No legal capacity or limited legal capacity;

10. Uncontrolled hypertension, or unsatisfactory blood pressure control with ≥3 antihypertensive drugs;